Is OKYO Pharma Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, OKYO Pharma Ltd (OKYO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is OKYO Pharma Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes OKYO Pharma Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of OKYO Pharma Ltd?

Muslim investors may consider investing in OKYO Pharma Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is OKYO Pharma Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of OKYO Pharma Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for OKYO Pharma Ltd updated?

The Shariah compliance status of OKYO Pharma Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like OKYO Pharma Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of OKYO Pharma Ltd?

You can check the latest Shariah compliance status of OKYO Pharma Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

OKYO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 28, 2026

Report Source: 2026 2nd Quarter Report

Analyst's Ratings for OKYO Pharma Ltd (OKYO)

Based on 10 analysts giving stock ratings to OKYO Pharma Ltd in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

OKYO Pharma Ltd. Stock Analysis OKYO

United States Health Care Micro Cap Report: Q2, 2026

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Key Statistics of OKYO Pharma Ltd (OKYO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.55$1.60

Today's Open

$1.58

Volume

71.06K

P/E Ratio (TTM)

52 Week Range

$1.36$3.35

Market Cap

82.19M

Avg. Volume

57.11K

Dividend Yield

Financial Metrics & Statements of OKYO Pharma Ltd (OKYO)

FAQ's for OKYO Pharma Ltd (OKYO)

According to Musaffa’s Shariah screening methodology, OKYO Pharma Ltd (OKYO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.